Shankaran Seetha, Pappas Athina, Laptook Abbott R, McDonald Scott A, Ehrenkranz Richard A, Tyson Jon E, Walsh Michelle, Goldberg Ronald N, Higgins Rosemary D, Das Abhik
Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA.
Pediatrics. 2008 Oct;122(4):e791-8. doi: 10.1542/peds.2008-0456.
Whole-body hypothermia reduced the frequency of death or moderate/severe disabilities in neonates with hypoxic-ischemic encephalopathy in a randomized, controlled multicenter trial.
Our goal was to evaluate outcomes of safety and effectiveness of hypothermia in infants up to 18 to 22 months of age.
DESIGN/METHODS: A priori outcomes were evaluated between hypothermia (n = 102) and control (n = 106) groups.
Encephalopathy attributable to causes other than hypoxia-ischemia at birth was not noted. Inotropic support (hypothermia, 59% of infants; control, 56% of infants) was similar during the 72-hour study intervention period in both groups. Need for blood transfusions (hypothermia, 24%; control, 24%), platelet transfusions (hypothermia, 20%; control, 12%), and volume expanders (hypothermia, 54%; control, 49%) was similar in the 2 groups. Among infants with persistent pulmonary hypertension (hypothermia, 25%; control, 22%), nitric-oxide use (hypothermia, 68%; control, 57%) and placement on extracorporeal membrane oxygenation (hypothermia, 4%; control, 9%) was similar between the 2 groups. Non-central nervous system organ dysfunctions occurred with similar frequency in the hypothermia (74%) and control (73%) groups. Rehospitalization occurred among 27% of the infants in the hypothermia group and 42% of infants in the control group. At 18 months, the hypothermia group had 24 deaths, 19 severe disabilities, and 2 moderate disabilities, whereas the control group had 38 deaths, 25 severe disabilities, and 1 moderate disability. Growth parameters were similar between survivors. No adverse outcomes were noted among infants receiving hypothermia with transient reduction of temperature below a target of 33.5 degrees C at initiation of cooling. There was a trend in reduction of frequency of all outcomes in the hypothermia group compared with the control group in both moderate and severe encephalopathy categories.
Although not powered to test these secondary outcomes, whole-body hypothermia in infants with encephalopathy was safe and was associated with a consistent trend for decreasing frequency of each of the components of disability.
在一项随机对照多中心试验中,全身低温降低了缺氧缺血性脑病新生儿的死亡或中重度残疾发生率。
我们的目标是评估18至22个月龄婴儿低温治疗的安全性和有效性结果。
设计/方法:对低温治疗组(n = 102)和对照组(n = 106)的先验结果进行评估。
未发现出生时缺氧缺血以外原因所致的脑病。在72小时的研究干预期内,两组使用血管活性药物支持的情况相似(低温治疗组为59%的婴儿,对照组为56%的婴儿)。两组输血需求(低温治疗组为24%,对照组为24%)、血小板输注需求(低温治疗组为20%,对照组为12%)和扩容剂使用情况(低温治疗组为54%,对照组为49%)相似。在持续性肺动脉高压婴儿中(低温治疗组为25%,对照组为22%),两组一氧化氮使用情况(低温治疗组为68%,对照组为57%)和体外膜肺氧合使用情况(低温治疗组为4%,对照组为9%)相似。低温治疗组(74%)和对照组(73%)非中枢神经系统器官功能障碍的发生频率相似。低温治疗组27%的婴儿再次住院,对照组42%的婴儿再次住院。18个月时,低温治疗组有24例死亡、19例重度残疾和2例中度残疾,而对照组有38例死亡、25例重度残疾和1例中度残疾。幸存者的生长参数相似。在降温开始时体温短暂降至低于33.5℃目标值的低温治疗婴儿中,未观察到不良结局。与对照组相比,在中度和重度脑病类别中,低温治疗组所有结局的发生频率均有降低趋势。
尽管无足够效能检验这些次要结局,但脑病婴儿的全身低温治疗是安全的,且与残疾各组成部分发生频率持续降低的趋势相关。